Atazanavir

Generic Name: Atazanavir

Brand Names: Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₅₂N_₆O_₇

CAS Number: 198904-31-3

Unique Ingredient Identifier: QZU4H47A3S

Background: Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.

Indication: Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

Not Applicable

Completed

Conditions: Endotoxemia
Inflammation
Multi Organ Dysfunction Syndrome
Sepsis

Interventions: Drug: Atazanavir
Drug: E. coli endotoxin

First Posted Date: 2009-06-09

Last Posted Date: 2015-08-14

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT00916448

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: tenofovir
Drug: emtricitabine
Drug: atazanavir
Drug: ritonavir

First Posted Date: 2009-03-26

Last Posted Date: 2013-09-06

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 24

Registration Number: NCT00869960

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Completed

Conditions: HIV Infection

Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate
Drug: Ritonavir
Drug: Atazanavir
Drug: Raltegravir
Drug: Darunavir

First Posted Date: 2009-02-26

Last Posted Date: 2016-01-13

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 334

Registration Number: NCT00851799

Locations: 🇺🇸
Harbor - UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸
Northwestern University CRS (2701), Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States

and more 23 locations

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Phase 1

Completed

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
HIV Infections

Interventions: Drug: Voriconazole
Drug: Atazanavir
Drug: Ritonavir

First Posted Date: 2009-02-02

Last Posted Date: 2012-10-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 185

Registration Number: NCT00833482

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇳🇱
Local Institution, Nijmegen, Netherlands

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Not Applicable

Completed

Conditions: HIV Infections
AIDS
Human Immunodeficiency Virus
Acquired Immune Deficiency Syndrome

Interventions: Other: Standard treatment regimen
Drug: Raltegravir
Drug: Atazanavir

First Posted Date: 2008-12-25

Last Posted Date: 2016-02-04

Lead Sponsor: Yale University

Target Recruit Count: 60

Registration Number: NCT00814879

Locations: 🇺🇸
Saint Raphael Healthcare System, New Haven, Connecticut, United States
🇺🇸
Waterbury Hospital, Waterbury, Connecticut, United States
🇺🇸
VA CT Healthcare Systems, West Haven, Connecticut, United States

and more 2 locations

Comparative Study of Three NNRTI-Sparing HAART Regimens

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate
Drug: Ritonavir
Drug: Raltegravir
Drug: Darunavir
Drug: Atazanavir

First Posted Date: 2008-12-19

Last Posted Date: 2014-09-05

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 1814

Registration Number: NCT00811954

Locations: 🇺🇸
The Ponce de Leon Center CRS, Atlanta, Georgia, United States
🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸
Trinity Health and Wellness Center, Dallas, Texas, United States

and more 54 locations

Phase IIB Pilot of Atazanavir + Raltegravir

Phase 2

Terminated

Conditions: HIV

Interventions: Drug: Atazanavir
Drug: Raltegravir
Drug: Ritonavir
Drug: Tenofovir/Emtricitabine

First Posted Date: 2008-10-08

Last Posted Date: 2012-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 167

Registration Number: NCT00768989

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇫🇷
Local Institution, Paris Cedex 20, France
🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States

and more 7 locations